ACKNOWLEDGMENTS
MALARIA
We thank the patients for their participation. The contributions of the study staff are acknowledged, including Cherinet Abebe, Alemseged Abdissa Lencho, Abebe Genetu Bayih, Gebrehiwot Lemma, Solomon Afework, Zeleke Alemu, Mubarik Taju, Meseret Birhanie Fentahune, Abdulhakim Abamecha Abafogi, Seid Amdala, Kaleab Eskinder, Gelila Meneberu, Rawuda Ebrhaim, Kinde W/Giyorgis, Eshetu Mulisa, Zerihun Befkadu, Bizuworek Sharew, Yeneneh Berhanu, Ligabaw Worku Gebremariam, Melese Abera, Mulugeta Aemro, Begosew Debas, Asnakew Engidaw, and Habtie Tesfa Delelegn. The contributions of Helen Demarest, Susan Podmore, and Charles Stoyanov for additional support in study management are acknowledged. We thank the Swiss Tropical Public Health Institute and Harald Noedl for their contributions to laboratory training during the study and Martina Wibberg of DATAMAP GmbH for statistical support. Naomi Richardson of Magenta Communications, funded by Medicines for Malaria Venture, wrote the first draft of this article and provided editorial and graphic services. The authors confirm that all ongoing and related trials for this drug/intervention are registered (#NCT02880241).This trial is registered at ClinicalTrials.gov (#NCT02880241, 